Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) had its price objective reduced by research analysts at Mizuho from $45.00 to $40.00 in a research note issued to investors on Wednesday. The firm presently has a “neutral” rating on the stock. Mizuho’s price target would suggest a potential upside of 6.38% from the company’s current price.

TEVA has been the topic of a number of other reports. RBC Capital Markets set a $71.00 target price on Teva Pharmaceutical Industries and gave the stock a “buy” rating in a report on Sunday, September 11th. Bank of America Corp. set a $72.00 target price on Teva Pharmaceutical Industries and gave the stock a “buy” rating in a report on Saturday, October 1st. Leerink Swann reaffirmed an “outperform” rating and issued a $66.00 target price on shares of Teva Pharmaceutical Industries in a report on Tuesday, August 16th. Piper Jaffray Cos. reissued a “neutral” rating and set a $57.00 price target (up from $55.00) on shares of Teva Pharmaceutical Industries in a report on Monday, August 8th. Finally, Oppenheimer Holdings Inc. cut Teva Pharmaceutical Industries from an “outperform” rating to a “market perform” rating and set a $70.29 price target on the stock. in a report on Friday, August 5th. Eleven investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $62.69.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Shares of Teva Pharmaceutical Industries (NYSE:TEVA) opened at 37.60 on Wednesday. The company has a market cap of $34.37 billion, a price-to-earnings ratio of 25.12 and a beta of 0.73. The stock has a 50 day moving average price of $43.93 and a 200-day moving average price of $50.26. Teva Pharmaceutical Industries has a 1-year low of $37.25 and a 1-year high of $66.55.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Tuesday, November 15th. The company reported $1.31 EPS for the quarter, topping the Zacks’ consensus estimate of $1.29 by $0.02. Teva Pharmaceutical Industries had a return on equity of 17.77% and a net margin of 7.56%. The company had revenue of $5.56 billion for the quarter, compared to analysts’ expectations of $5.71 billion. During the same period last year, the firm earned $1.35 EPS. Teva Pharmaceutical Industries’s revenue for the quarter was up 15.3% compared to the same quarter last year. Equities research analysts forecast that Teva Pharmaceutical Industries will post $5.16 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 20th. Stockholders of record on Monday, December 5th will be paid a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 3.62%. Teva Pharmaceutical Industries’s dividend payout ratio is presently 58.39%.

Several hedge funds have recently bought and sold shares of TEVA. Franklin Resources Inc. increased its stake in Teva Pharmaceutical Industries by 11.9% in the second quarter. Franklin Resources Inc. now owns 41,211,549 shares of the company’s stock valued at $2,070,095,000 after buying an additional 4,389,590 shares in the last quarter. Barrow Hanley Mewhinney & Strauss LLC increased its position in shares of Teva Pharmaceutical Industries by 143.7% in the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 22,700,812 shares of the company’s stock worth $1,140,263,000 after buying an additional 13,385,352 shares during the period. Capital Research Global Investors increased its position in shares of Teva Pharmaceutical Industries by 20.9% in the third quarter. Capital Research Global Investors now owns 20,875,749 shares of the company’s stock worth $960,493,000 after buying an additional 3,609,949 shares during the period. Waddell & Reed Financial Inc. increased its position in shares of Teva Pharmaceutical Industries by 4.9% in the second quarter. Waddell & Reed Financial Inc. now owns 19,358,468 shares of the company’s stock worth $972,375,000 after buying an additional 896,033 shares during the period. Finally, Bank of New York Mellon Corp increased its position in shares of Teva Pharmaceutical Industries by 8.4% in the third quarter. Bank of New York Mellon Corp now owns 16,124,966 shares of the company’s stock worth $741,908,000 after buying an additional 1,256,324 shares during the period. 63.00% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.

5 Day Chart for NYSE:TEVA

Receive News & Stock Ratings for Teva Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd. and related stocks with our FREE daily email newsletter.